Endocrine Abstracts

Introduction: There is strong evidence that adult survivors of childhood cancer have excess premature vascular morbidity and mortality, the pathophysiological mechanism of which remains unresolved.Methods: We undertook a cross sectional study to assess cardiovascular risk in long-term survivors of brain tumours following cranial irradiation compared with healthy matched controls. The following cardiovascular markers were measured: full lipid profile, fas...

Introduction: Radiation-induced hypopituitarism is a well-recognized complication of cranial radiotherapy (cXRT) for childhood brain tumours when the hypothalamo–pituitary axis is within the irradiation field. Few data are available for survivors of adult brain tumours who have received cranial irradiation.Methods: We retrospectively reviewed medical records of patients referred to Endocrinology following cXRT for primary non-pituitary brain tumours...

Introduction: PATRO adults is an ongoing, international, open, longitudinal, non-interventional study of the long-term safety and efficacy of recombinant human GH (rhGH; Omnitrope, Sandoz). The study will provide further data on the long-term safety of rhGH in adult patients with severe GH deficiency (GHD). Here, we present safety data from an interim analysis.Methods: Adults who are receiving treatment with Omnitrope and who have provided informed conse...

Introduction: PATRO adults is an ongoing, international, open, longitudinal, non-interventional study of the long-term safety and efficacy of Omnitrope (Sandoz), a recombinant human GH (rhGH). This study will provide additional data on the long-term safety of rhGH in adult patients with severe GH deficiency (GHD). Here, we present safety data from an interim analysis.Methods: Eligible patients are male or female adults who are receiving treatment with Om...

Patients with GHD have an, adverse body composition, insulin resistance, atherogenic lipid profile and impaired quality of life. We undertook a single centre retrospective audit of hypopituitary adults to quantify the long-term effects of dose-titrated GH replacement.The cohort comprised 53 patients defined as severely GHD using the GST (median peak GH 2.4 μ/l). Mean age 42±16.9 years, 23F, BMI 29.3±5.3 kg/m2. GH was titrated un...

Background: Growth Hormone (GH) and insulin-like growth factor 1 (IGF-1) are the biomarkers used to assess disease activity in acromegaly. Consensus guidelines from the Endocrine Society (2014) recommend a normal (age/sex-adjusted) IGF-1 in combination with a suppressed random GH<1 μg/l for biochemical remission. However, these results are discordant in some patients. The clinical significance of the IGF-1/GH dichotomy in the follow-up of these patients is unclear and...

Background: Acromegaly is characterised by growth hormone (GH) and insulin-like growth factor (IGF-1) hypersecretion. The disease is associated with increased cardiovascular, cerebrovascular and metabolic co-morbidities, resulting in excess mortality. A target GH <1 μg/l and normalised IGF-1 values correlate with mortality risk reduction. However, there is lack of consensus over which biomarker, GH or IGF-1, better predicts increased morbidity and/ or mortality.<p...

Background: Non-functioning pituitary adenomas (NFPA) account for 30-35% of pituitary adenomas. They can lead to hypopituitarism and visual field defects. Trans-sphenoidal resection of pituitary adenoma remains the treatment of choice.Methods: We compared clinical, biochemical, and imaging characteristics of NFPAs at presentation with post-surgical outcomes in a retrospective cohort study. Patients who underwent end...

Background: Non-functioning pituitary adenomas (NFPA) account for 30-35% of pituitary adenomas. They can lead to hypopituitarism and visual field defects. Trans-sphenoidal resection of pituitary adenoma remains the treatment of choice.Methods: We compared clinical, biochemical, and imaging characteristics of NFPAs at presentation with post-surgical outcomes in a retrospective cohort study. Patients who underwent end...

Introduction: Radiotherapy (RT) can achieve tumour control rates of over 90% in patients with pituitary adenomas. The commonest toxicity of irradiation is hypopituitarism. The exact incidence is variable and requires long-term intermittent testing for deficiency of all hypothalamic−pituitary axes (HPA). The aim of this study is to determine the time to onset of individual hormonal deficiencies and establish a time frame for endocrine testing during follow-up post-RT....